An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
| Status: | Completed |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/30/2013 |
| Start Date: | June 2013 |
| End Date: | January 2014 |
| Contact: | P Brian Smith, MD MHS |
| Email: | brian.smith@duke.edu |
| Phone: | 9196688951 |
This is a phase I open label multi-dose study to investigative the pharmacokinetics and
safety of cefazolin in infants <121 days of age and < 28 weeks gestation with suspected
sepsis. There will be two cohorts of 6 infants each: 1) >48 hours of age and ≤28 days and
2) >28 days of age and <121 days of age. The study requires administration of the study drug
over 2 days followed by 1 week of safety monitoring. Six 200 µL pK samples will be obtained
over the 2 days of drug administration. The risks are reasonable vs. the benefits and have
been minimized appropriately. There may be benefit to the subjects (administration of
empirical antimicrobial therapy), and information from the study may benefit a large number
of other infants in whom the drug is currently being administered despite the lack of PK
data in this population.
Inclusion Criteria:
- < 28 weeks gestation at birth
- > 48 hours and <121 days of age at the time of study drug administration
- One of the following:
- Suspected systemic infection
- Receiving cefazolin for prophylaxis
- Receiving cefazolin treatment of a systemic infection
Exclusion Criteria:
- History of anaphylaxis attributed to a β-lactam
- Exposure to cefazolin in the month prior to study
- Serum creatinine > 1.7 mg/dL
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
